• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化治疗共识小组(MSTCG):关于多发性硬化疾病修正疗法的立场声明(白皮书)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).

作者信息

Wiendl Heinz, Gold Ralf, Berger Thomas, Derfuss Tobias, Linker Ralf, Mäurer Mathias, Aktas Orhan, Baum Karl, Berghoff Martin, Bittner Stefan, Chan Andrew, Czaplinski Adam, Deisenhammer Florian, Di Pauli Franziska, Du Pasquier Renaud, Enzinger Christian, Fertl Elisabeth, Gass Achim, Gehring Klaus, Gobbi Claudio, Goebels Norbert, Guger Michael, Haghikia Aiden, Hartung Hans-Peter, Heidenreich Fedor, Hoffmann Olaf, Kallmann Boris, Kleinschnitz Christoph, Klotz Luisa, Leussink Verena I, Leutmezer Fritz, Limmroth Volker, Lünemann Jan D, Lutterotti Andreas, Meuth Sven G, Meyding-Lamadé Uta, Platten Michael, Rieckmann Peter, Schmidt Stephan, Tumani Hayrettin, Weber Frank, Weber Martin S, Zettl Uwe K, Ziemssen Tjalf, Zipp Frauke

机构信息

Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster.

Neurologie, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, Gudrunstraße 56, 44791 Bochum, Germany.

出版信息

Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021.

DOI:10.1177/17562864211039648
PMID:34422112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8377320/
Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

摘要

多发性硬化症是一种复杂的、自身免疫介导的中枢神经系统疾病,其特征为炎症性脱髓鞘以及轴突/神经元损伤。近年来,多种疾病修正疗法的获批以及我们对疾病机制和演变的深入了解,显著改变了该疾病的预后和病程。多发性硬化症治疗共识小组治疗建议的此次更新聚焦于2021年多发性硬化症疾病修正疗法的最重要建议。我们的建议基于当前的科学证据,适用于在欧洲大部分地区获批的药物,尤其是德语国家(德国、奥地利和瑞士)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a01f/8377320/8ae811002fac/10.1177_17562864211039648-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a01f/8377320/8ae811002fac/10.1177_17562864211039648-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a01f/8377320/8ae811002fac/10.1177_17562864211039648-fig1.jpg

相似文献

1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).多发性硬化治疗共识小组(MSTCG):关于多发性硬化疾病修正疗法的立场声明(白皮书)
Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021.
2
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].[多发性硬化治疗共识小组(MSTCG):2021年多发性硬化疾病修正治疗立场文件(白皮书)]
Nervenarzt. 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23.
3
Update on disease-modifying therapies for multiple sclerosis.多发性硬化症疾病修正疗法的最新进展。
J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.
4
Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.多发性硬化的对症治疗。德国多发性硬化协会多发性硬化治疗共识小组(MSTCG)
Eur Neurol. 2006;56(2):78-105. doi: 10.1159/000095699. Epub 2006 Sep 8.
5
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.西班牙神经病学学会2016年关于多发性硬化症治疗的共识声明。
Neurologia. 2017 Mar;32(2):113-119. doi: 10.1016/j.nrl.2016.02.026. Epub 2016 May 6.
6
Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity.根据疾病活动情况选择多发性硬化症患者的疾病修正治疗的阿拉伯海湾专家共识。
Postgrad Med. 2020 May;132(4):368-376. doi: 10.1080/00325481.2020.1734394. Epub 2020 Feb 28.
7
Established and novel disease-modifying treatments in multiple sclerosis.多发性硬化症的既定和新型疾病修正治疗方法。
J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11.
8
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.多发性硬化症:现有和新兴的疾病修正治疗方法和治疗策略。
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
9
[Current aspects of therapy conversion for multiple sclerosis].[多发性硬化症治疗转换的当前方面]
Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8.
10
Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.儿童和青少年遗传性血管性水肿——德语国家治疗策略的共识更新
Pediatr Allergy Immunol. 2020 Nov;31(8):974-989. doi: 10.1111/pai.13309. Epub 2020 Jul 16.

引用本文的文献

1
Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.多发性硬化症患者转换高效疾病修正治疗的年龄相关差异。
J Neurol. 2025 Sep 4;272(9):609. doi: 10.1007/s00415-025-13330-7.
2
Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment.超越疗效:一线多发性硬化症治疗中的持续治疗、无疾病活动证据状态及治疗决策
Neurol Ther. 2025 Aug 12. doi: 10.1007/s40120-025-00811-0.
3
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.

本文引用的文献

1
The potential of serum neurofilament as biomarker for multiple sclerosis.血清神经丝作为多发性硬化症生物标志物的潜力。
Brain. 2021 Nov 29;144(10):2954-2963. doi: 10.1093/brain/awab241.
2
2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.2021 年 MAGNIMS-CMSC-NAIMS 关于多发性硬化症患者使用 MRI 的共识建议。
Lancet Neurol. 2021 Aug;20(8):653-670. doi: 10.1016/S1474-4422(21)00095-8. Epub 2021 Jun 14.
3
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
多发性硬化症高效疾病修正疗法的应用:专家德尔菲共识推荐意见
J Neurol. 2025 Aug 10;272(9):565. doi: 10.1007/s00415-025-13293-9.
4
Application of telemedicine in fatigue management for patients with multiple sclerosis: A scoping review.远程医疗在多发性硬化症患者疲劳管理中的应用:一项范围综述。
PLoS One. 2025 Jul 17;20(7):e0327563. doi: 10.1371/journal.pone.0327563. eCollection 2025.
5
De-Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria.奥地利复发型多发性硬化症患者从那他珠单抗转换治疗的策略
Eur J Neurol. 2025 Jul;32(7):e70282. doi: 10.1111/ene.70282.
6
Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry.与其他用于治疗多发性硬化症的疾病修正疗法相比,奥瑞珠单抗的持久性:来自德国神经转运数据登记处的结果。
Neurol Ther. 2025 Jun 2. doi: 10.1007/s40120-025-00762-6.
7
Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder.一项针对多发性硬化症和视神经脊髓炎谱系障碍的长期免疫调节的真实世界研究中的非典型不良事件。
Ther Adv Neurol Disord. 2025 Apr 4;18:17562864251320206. doi: 10.1177/17562864251320206. eCollection 2025.
8
Shifts in treatment initiation patterns among newly diagnosed multiple sclerosis patients in Germany: a claims data analysis from 2017 to 2022.德国新诊断多发性硬化症患者治疗起始模式的变化:2017年至2022年索赔数据分析
Ther Adv Neurol Disord. 2025 Apr 17;18:17562864251328576. doi: 10.1177/17562864251328576. eCollection 2025.
9
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort.瑞士多发性硬化症队列中开始使用B细胞耗竭疗法的患者的治疗持续性和临床结局
Mult Scler J Exp Transl Clin. 2025 Feb 26;11(1):20552173251315457. doi: 10.1177/20552173251315457. eCollection 2025 Jan-Mar.
10
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.间充质干细胞治疗多发性硬化症的最新进展:临床应用与挑战
Front Cell Dev Biol. 2025 Feb 3;13:1517369. doi: 10.3389/fcell.2025.1517369. eCollection 2025.
北美多发性硬化症患者SARS-CoV-2感染的相关结局和风险因素
JAMA Neurol. 2021 Jun 1;78(6):699-708. doi: 10.1001/jamaneurol.2021.0688.
4
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.原发性进行性多发性硬化症中需要轮椅的风险:来自 ORATORIO 试验和 MSBase 登记处的数据。
Eur J Neurol. 2022 Apr;29(4):1082-1090. doi: 10.1111/ene.14824. Epub 2021 May 6.
5
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.在接受阿仑单抗治疗的多发性硬化症患者中,既往疾病修正治疗对疗效和安全性结局的影响。
J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):1007-1013. doi: 10.1136/jnnp-2020-325304. Epub 2021 Mar 12.
6
Diagnosis and Treatment of Multiple Sclerosis: A Review.多发性硬化症的诊断与治疗:综述。
JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858.
7
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials.衰老与多发性硬化症疾病修正疗法的疗效:一项临床试验的荟萃分析
Ther Adv Neurol Disord. 2020 Oct 28;13:1756286420969016. doi: 10.1177/1756286420969016. eCollection 2020.
8
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.使用一个新的数据集(NO.MS 队列)整合 34 项临床试验,对跨越年龄范围的多发性硬化症表型进行特征描述:年龄是影响表现的关键因素。
Mult Scler. 2021 Nov;27(13):2062-2076. doi: 10.1177/1352458520988637. Epub 2021 Jan 28.
9
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
10
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.疾病修正疗法对复发缓解型多发性硬化症 15 年残疾进展的影响。
Neurology. 2021 Feb 2;96(5):e783-e797. doi: 10.1212/WNL.0000000000011242. Epub 2020 Dec 28.